Modafinil: A Review of Neurochemical Actions and Effects on Cognition
The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term 'modafinil' and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including workin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, side effects of alpha agonists like guanfacine and clonidine include high prevalence of somnolence or sedating effects,168,169”
From Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome (2023) · cites this paper as [168]
In the citing paper
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472 · cited 7×
“Importantly, modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described in the Aston…”
BackgroundMethodResultInfluentialNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 3×
“m Fos in orexin neurons in perfornical area 150 mg/kg i.p. Immunohisto-chemistry Mice Chemelli et al, 1999 75 mg/kg i.p. Immunohisto-chemistry Rat Scammell et al, 2000 No binding to orexin-1 receptor IC50 410mM 125I-human-orexin B displacement Transfected Chinese Hamster Ovary cells Wieland et al,…”
BackgroundAston-Jones, G., & Bloom, F. (1981) · The Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00876.1981 · Cited by 1,960 · cited 1×
“It appears also that when levels of tonic LC activity are minimal, such as during sleep, grooming, and eating, that phasic responses are also less robust (Aston-Jones and Bloom, 1981).”
BackgroundTask-evoked pupillary responses, processing load, and the structure of processing resources.
Beatty, J. (1982) · Psychological Bulletin · doi:10.1037/0033-2909.91.2.276 · Cited by 1,959 · cited 1×
“…modafinil also augments pupillary dilation parameters (Hou et al, 2005) in a manner consistent with LC phasic responses to task-relevant events (Beatty, 1982a, b; Richer and Beatty, 1987), suggesting the potential for LC/NE system effects in optimizing cognitive task performance, as described…”
The principal features and mechanisms of dopamine modulation in the prefrontal cortex
Seamans, J. K., & Yang, C. R. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.006 · Cited by 1,592 · cited 15×
“Inhibition of DA cell firing in VTA/SN; blocked by Sulpiride 10mM but not by Prazosin 20 mM Extracellular recording Rat brain slice Korotkova et al, 2006 Hyperpolarization of VTA neurons, blocked by Sulpiride 10mM 20–50mM Whole-cell patch clamp Isolated VTA neurons No effect on mesencephalic DA neuron activity 128 mg/…”
BackgroundInfluentialDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929 · cited 5×
“Thalamic NET occupancy: 16, 44% 5, 8 mg/kg i.v. PET with [11C]MeNER Rhesus monkey Madras et al, 2006 NET binding IC50¼ 35.6mM [3H] NE Human Embryo Kidney No effect on pontine NE neuron activity 128 mg/kg i.p. Single-unit recording Rat (anesthetized) Akaoka et al, 1991 Extracellular NE: m in PFC, medial hypothalamus 12…”
BackgroundInfluentialDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769 · cited 7×
“…extracellular DA levels (measured by microdialysis) that are increased significantly in the rat prefrontal cortex (PFC) (de Saint Hilaire et al, 2001), and in the caudate nucleus of narcoleptic dogs (Wisor et al, 2001), although only minimally in the rat hypothalamus (de Saint Hilaire et al, 2001).”
BackgroundInfluentialThe role of locus coeruleus in the regulation of cognitive performance
Usher, M., Cohen, J. D., Servan-Schreiber, D., Rajkowski, J., & Aston-Jones, G. (1999) · Science · doi:10.1126/science.283.5401.549 · Cited by 715
Research works printed but not linked: 1
- Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC et al (1999b). A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39: 30–40. · DOI · Paper page
Cited by
Items 101–200 of 735
Raineri, M., González, B., Goitia, B., García‐Rill, E., Krasnova, I. N., Cadet, J. L., Urbano, F. J., & Bisagno, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046599 · Cited by 82
“modafinil causes a dose dependent decrease of GABA in rat cortex, hypothalamus, thalamus, substantia nigra, hippocampus and also in dorsal and ventral striatum (reviewed in [46]).”
BackgroundCooper, J. A., Tucker, V. L., & Papakostas, G. I. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113514878 · Cited by 76
“Although the precise mechanism of action of modafinil is unknown, it is postulated to be mediated via dopamine and noradrenaline (Minzenberg and Carter, 2008).”
BackgroundMillan, M. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001496 · Cited by 79
“Modafinil revealed modest and possibly non-sustained improvements in mood upon addition to SSRIs and, not surprisingly in view of its wake-promoting characteristics, reduced fatigue (Minzenberg and Carter, 2008; Shelton et al., 2010; Connolly and Thase, 2012; Millan, 2013).”
BackgroundAcute Modafinil Effects on Attention and Inhibitory Control in Methamphetamine-Dependent Humans
Dean, A. C., Sevak, R. J., Monterosso, J. R., Hellemann, G., Sugar, C. A., & London, E. D. (2011) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2011.72.943 · Cited by 79
“The specifi c mechanism by which modafi nil produces these effects has not been identifi ed, but modafi nil increases extracellular levels of dopamine, norepinephrine, serotonin, glutamate, and histamine, and it decreases γ-aminobutyric acid levels (Minzenberg and Carter, 2008).”
BackgroundMethodPsychostimulant Treatment of Cocaine Dependence
Mariani, J. J., & Levin, F. R. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.012 · Cited by 80
Pharmakologisches Neuroenhancement und „Hirndoping“: Chancen und Risiken
Franke, A. G., & Lieb, K. (2010) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-010-1105-0 · Cited by 93
Roberts, C. A., Jones, A., Sumnall, H., Gage, S. H., & Montgomery, C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.07.002 · Cited by 78
Practical Use and Risk of Modafinil, a Novel Waking Drug
Kim, D. (2012) · Environmental Health and Toxicology · doi:10.5620/eht.2012.27.e2012007 · Cited by 73
“There is substantial evidence that modafinil, just like other addictive drugs, is sensitive to dopamine signaling in the brain [30,45-47].”
BackgroundSchmaal, L., Goudriaan, A. E., Joos, L., Krüse, A. M., Dom, G., van den Brink, W., & Veltman, D. J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.12.025 · Cited by 82
“These widespread effects of modafinil seem to match the effects of modafinil on a broad range of neurotransmitters, including dopamine, noradrenaline, glutamate, serotonin and GABA (Minzenberg & Carter 2008).”
BackgroundHildt, E., Lieb, K., & Franke, A. G. (2014) · BMC Medical Ethics · doi:10.1186/1472-6939-15-23 · Cited by 85
“subjects compared to non-sleep-deprived subjects [5-7].”
New horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 85
Repantis, D., Bovy, L., Ohla, K., Kühn, S., & Dresler, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05691-w · Cited by 88
“Its mode of action is less clear, but it seems that it increases extracellular catecholamine levels and indirectly activates the hypocretinergic system (Minzenberg and Carter 2008).”
BackgroundMethodStrategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.53 · Cited by 73
“Minzenberg and colleagues postulate that modafinil largely affects brain catecholamines, inhibiting both the dopamine transporter and the norepinephrine transporter, and elevating the extracellular concentrations of glutamate, serotonin and histamine, while also activating the orexin system and decreasing GABA in the…”
BackgroundSalagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71
Qiu, M.-H., Liu, W., Qu, W.-M., Urade, Y., Lu, J., & Huang, Z.-L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045471 · Cited by 70
“Modafinil is one of most popular stimulants [13,14].”
BackgroundSahu, S., Kauser, H., Ray, K., Kishore, K., Kumar, S., & Panjwani, U. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.021 · Cited by 76
“Besides neurotransmitter modulation there is very little literature available on the mechanism of action of modafinil on cognition during SD or any other conditions (Minzenberg and Carter, 2008).”
BackgroundCognitive Enhancement in Canadian Medical Students
Kudlow, P. A., Naylor, K. T., Xie, B., & McIntyre, R. S. (2013) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2013.825033 · Cited by 74
Cognitive enhancers for anxiety disorders
Hofmann, S. G., Smits, J. A. J., Asnaani, A., Gutner, C. A., & Otto, M. W. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.020 · Cited by 68
“Preclinical data suggest that modafinil can improve working memory performance in a doseand delay-dependent manner, that the processing of contextual cues is enhanced with modafinil, and that these effects may be augmented with sustained dosing regimens (for a review, see Minzenberg & Carter, 2008).”
BackgroundMethodFarah, M. J., Smith, M. E., Ilieva, I. P., & Hamilton, R. H. (2013) · Wiley Interdisciplinary Reviews Cognitive Science · doi:10.1002/wcs.1250 · Cited by 85
Modafinil decreases anxiety-like behaviour in zebrafish
Johnson, A. S., & Hamilton, T. J. (2017) · PeerJ · doi:10.7717/peerj.2994 · Cited by 71
Connexin-Dependent Neuroglial Networking as a New Therapeutic Target
Charvériat, M., Naus, C. C. G., Leybaert, L., Sáez, J. C., & Giaume, C. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00174 · Cited by 70
“, 2016) with a complex mechanism of action (Minzenberg and Carter, 2008), enhances astroglial Cx and more precisely Cx30 expression and GJ function (Liu et al.”
BackgroundCognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68
“Modafinil has demonstrated potential procognitive effects in healthy voluntaries and it has been investigated in some clinical populations (Minzenberg and Carter, 2008).”
BackgroundLuppi, A. I., Hansen, J. Y., Ram, A., Carhart-Harris, R. L., Roseman, L., Timmermann, C., Golkowski, D., Ranft, A., Ilg, R., Jordan, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8332 · Cited by 75
Kalechstein, A. D., De La Garza, II, & Newton, T. F. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00052.x · Cited by 67
Neale, C., Camfield, D., Reay, J., Stough, C., & Scholey, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12002 · Cited by 66
Pharmacological Approaches for Treatment-resistant Bipolar Disorder
Poon, S. H., Sim, K., & Baldessarini, R. J. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171954 · Cited by 74
“Modafinil and its active R-enantiomer, armodafinil are mild stimulant-like agents with complex neuropharmacological actions that include inhibition of dopamine reuptake, similar to other stimulants, and they are used primarily to treat narcolepsy [90,91].”
BackgroundAcute effects of modafinil on brain resting state networks in young healthy subjects
Esposito, R., Cilli, F., Pieramico, V., Ferretti, A., Macchia, A., Tommasi, M., Saggino, A., Ciavardelli, D., Manna, A., Navarra, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069224 · Cited by 66
“This result is in accordance with investigation employing modafinil to compensate frank cognitive deficits in psychiatric patients [52].”
The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory
Wigmore, P. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_235 · Cited by 66
Methamphetamine and sleep impairments: neurobehavioral correlates and molecular mechanisms
Vrajová, M., Šlamberová, R., Höschl, C., & Ovsepian, S. V. (2021) · SLEEP · doi:10.1093/sleep/zsab001 · Cited by 67
Modafinil modulation of the default mode network
Minzenberg, M. J., Yoon, J. H., & Carter, C. S. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2111-5 · Cited by 63
“Additionally, there is evidence that modafinil affects levels of other extracellular neurotransmitters such as serotonin and amino acid neurotransmitters; however, there is no evidence that this agent binds directly to elements of these other neurotransmitter systems, suggesting that these latter effects are mediated…”
BackgroundInfluentialSelf-citationReality of evidence-based practice in palliative care.
Visser, C., Hadley, G., & Wee, B. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0041 · Cited by 91
Rowley, H. L., Kulkarni, R. S., Gosden, J., Brammer, R. J., Hackett, D., & Heal, D. J. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513850 · Cited by 65
“Although modafinil has only low millimolar affinity for DAT (Madras et al., 2006; Zolkowska et al., 2009) and no affinity for NET or 5-hydroxytryptamine transporter (SERT) (Madras et al., 2006; Minzenberg and Carter, 2008), positron emission tomography experiments in humans have paradoxically revealed that therapeutic…”
BackgroundPaterson, N. E., Fedolak, A., Olivier, B., Hanania, T., Ghavami, A., & Caldarone, B. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.006 · Cited by 66
“The pharmacological properties of modafinil are not yet entirely clear, but appear to include effects on norepinephrine, serotonin, glutamate, GABA, histamine and orexin signaling (for review, see Minzenberg and Carter, 2008).”
SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues
Cao, J., Prisinzano, T. E., Okunola, O. M., Kopajtic, T. A., Shook, M., Katz, J. L., & Newman, A. H. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1002025 · Cited by 69
Impact of Astroglial Connexins on Modafinil Pharmacological Properties
Duchêne, A., Perier, M., Zhao, Y., Liu, X., Thomasson, J., Chauveau, F., Piérard, C., Lagarde, D., Picoli, C., Jeanson, T., et al. (2016) · SLEEP · doi:10.5665/sleep.5854 · Cited by 63
“An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.”
BackgroundLapid, M. I., Kuntz, K. M., Mason, S. S., Aakre, J. A., Lundt, E. S., Kremers, W., Allen, L. A., Drubach, D. A., & Boeve, B. F. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000471507 · Cited by 61
Olson, K. J., & Sands, S. A. (2015) · Child Neuropsychology · doi:10.1080/09297049.2015.1049941 · Cited by 66
“…receptors, although these have yet to be as thoroughly studied—and is associated with demonstrated improvement in WM and information processing in both rodent models and adult human clinical trials to improve wakefulness in adults who experience excessive sleepiness (Minzenberg & Carter, 2008).”
BackgroundCognitive Enhancement in Schizophrenia
Harvey, P. D., & Bowie, C. R. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.06.008 · Cited by 64
“Cognitive enhancement in healthy individuals is also reported with modafinil, but these improvements are much more substantial in individuals who are sleep deprived at baseline (60).”
BackgroundGoudriaan, A. E., Veltman, D. J., van den Brink, W., Dom, G., & Schmaal, L. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.04.006 · Cited by 64
“It has been suggested that modafinil exerts its primary effects on the catecholamine system, including the dopamine and noradrenalin neurotransmitter systems (Minzenberg & Carter, 2008).”
Horton, D. B., Potter, D. M., & Mead, A. N. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283644d2e · Cited by 61
Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers
Winder-Rhodes, S., Chamberlain, Sr., Idris, M., Robbins, T., Sahakian, B., & Müller, U. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109105899 · Cited by 59
“The dose of modafinil was consistent with that used in certain previous studies that have demonstrated significant cognitive effects of this agent in healthy volunteers (Minzenberg and Carter, 2008; Müller, et al., 2004).”
BackgroundResultInfluentialBisagno, V., González, B., & Urbano, F. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.013 · Cited by 59
Luppi, A. I., Singleton, S. P., Hansen, J. Y., Jamison, K. W., Bzdok, D., Kuceyeski, A. F., Betzel, R. F., & Mišić, B. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01242-2 · Cited by 73
González, B., Raineri, M., Cadet, J. L., García‐Rill, E., Urbano, F. J., & Bisagno, V. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.002 · Cited by 63
“Modafinil showed lower liability to abuse and lower risk of adverse effects on organ systems including the cardiovascular system (Minzenberg and Carter, 2008).”
BackgroundSteiner, H., & Waes, V. V. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.10.001 · Cited by 65
“These psychostimulant medications are valued and widely prescribed for their efficacy in controlling symptoms of attentiondeficit hyperactivity disorder (ADHD) (methylphenidate, amphetamine) or excessive daytime sleepiness associated with narcolepsy and other sleep disorders (modafinil, amphetamine, methylphenidate) (…”
InfluentialHow to Keep the Brain Awake? The Complex Molecular Pharmacogenetics of Wake Promotion
Hasan, S., Pradervand, S., Ahnaou, A., Drinkenburg, W. H. I. M., Tafti, M., & Franken, P. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.3 · Cited by 59
Drugs, games, and devices for enhancing cognition: implications for work and society
Brühl, A. B., & Sahakian, B. J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13040 · Cited by 61
Kaser, M., Deakin, J. B., Michael, A., Zapata, C., Bansal, R., Ryan, D., Cormack, F., Rowe, J. B., & Sahakian, B. J. (2017) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2016.11.009 · Cited by 56
“The actions of modafinil on norepinephrine and dopamine in dorsolateral prefrontal regions likely play a role in improved working memory performance (34,35).”
BackgroundCognitive Deficit in Schizophrenia: From Etiology to Novel Treatments
Martínez, A. L., Brea, J. M., Rico, S., Frailes, M. T. D. L., & Loza, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189905 · Cited by 65
Michalopoulou, P. G., Lewis, S. W., Drake, R., Reichenberg, A., Emsley, R., Kalpakidou, A. K., Lees, J., Bobin, T., Gilleen, J., Pandina, G., et al. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.03.009 · Cited by 59
Bakare, O. M., Cao, J., Kopajtic, T. A., Katz, J. L., Loland, C. J., Shi, L., & Newman, A. H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401754x · Cited by 57
Martínez-Raga, J., Knecht, C., & Cepeda, S. (2008) · Current Drug Abuse Reviews · doi:10.2174/1874473710801020213 · Cited by 59
The ethics of elective psychopharmacology
Mohamed, A. D., & Sahakian, B. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100037x · Cited by 68
“For example, to exert its cognitive enhancing effects, modafinil has been shown to elevate numerous neurotransmitters including NA, DA and glutamate (Minzenberg & Carter, 2008 ; Volkow et al. 2009).”
BackgroundExploring the Effect of Ginsenoside Rh1 in a Sleep Deprivation‐Induced Mouse Memory Impairment Model
Lü, C., Shi, Z., Dong, L., Lv, J., Xu, P., Li, Y., Qu, L., & Liu, X. (2017) · Phytotherapy Research · doi:10.1002/ptr.5797 · Cited by 58
ADHD: Current and Future Therapeutics
Heal, D. J., Smith, S. L., & Findling, R. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_125 · Cited by 64
Pupil diameter reflects uncertainty in attentional selection during visual search
Geng, J. J., Blumenfeld, Z., Tyson, T. L., & Minzenberg, M. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00435 · Cited by 68
“Uncertainty and mental effort may be inextricably linked with pupil diameter if uncertainty triggers phasic activity in the LC-NE system associated with prefrontal cognitive control mechanisms that may help improve the likelihood of correct performance (Minzenberg and Carter, 2008).”
BackgroundSelf-citationDawson, N., Xiao, X., McDonald, M., Higham, D. J., Morris, B. J., & Pratt, J. A. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs322 · Cited by 55
Dopamine Receptor Mediation of the Exploratory/Hyperactivity Effects of Modafinil
Young, J. W., Kooistra, K., & Geyer, M. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.23 · Cited by 56
Protective effects of Genistein on the cognitive deficits induced by chronic sleep deprivation
Lü, C., Lv, J., Jiang, N., Wang, H., Huang, H. M., Zhang, L., Li, S., Zhang, N., Fan, B., Liu, X., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6567 · Cited by 56
“…of studies using rodents in different memory tasks and behavioral states such as spatial working and long‐term memory, attention, impulsive behavior, and speed of response and accuracy confirmed the cognitive enhancing effects of MOD, which was a wake‐promoting drug (Minzenberg & Carter, 2008).”
BackgroundAndrade, C., Kisely, S. R., Monteiro, I., & Rao, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.013 · Cited by 53
Joos, L., Goudriaan, A. E., Schmaal, L., Fransén, E., van den Brink, W., Sabbe, B., & Dom, G. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.004 · Cited by 59
“Modafinil (2-[(diphenylmethyl) sulfinyl] acetamide) is a wakefulness-promoting drug that is currently approved for the treatment of narcolepsy, but is also used for its cognitive enhancement (for review see Joos et al., 2010; Minzenberg and Carter, 2008).”
Use of Stimulants in Bipolar Disorder
Perugi, G., Vannucchi, G., Bedani, F., & Favaretto, E. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0758-x · Cited by 50
Omoluabi, T., Torraville, S. E., Maziar, A., Ghosh, A., Power, K. D., Reinhardt, C., Harley, C. W., & Yuan, Q. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12231 · Cited by 61
Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse
Reichel, C. M., & See, R. E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1828-5 · Cited by 60
“The structurally distinct nature of modafinil relative to many classic stimulant drugs may contribute to its unique behavioral profile (reviewed in Minzenberg and Carter 2008).”
BackgroundMitchell, H. A., Bogenpohl, J. W., Liles, L. C., Epstein, M. P., Bozyczko-Coyne, D., Williams, M., & Weinshenker, D. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.014 · Cited by 51
“Modafinil has a behavioral phenotype distinct from that of more traditional stimulants such as amphetamine or cocaine in that it does not produce rebound hypersomnolence and has limited dependence liability (Ballon and Feifel, 2006; Edgar and Seidel, 1997; Minzenberg and Carter, 2008).”
BackgroundCognitive Remediation in Schizophrenia
Kaneko, Y., & Keshavan, M. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.3.125 · Cited by 51
Apathy and Motivation: Biological Basis and Drug Treatment
Costello, H., Husain, M., & Roiser, J. P. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022423-014645 · Cited by 63
Addictive potential of modafinil and cross‐sensitization with cocaine: a pre‐clinical study
Wuo‐Silva, R., Fukushiro, D. F., Borçoi, A. R., Fernandes, H. A., Procópio‐Souza, R., Hollais, A. W., Santos, R., Ribeiro, L. T. C., Corrêa, J. M. R. M., Talhati, F., et al. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00341.x · Cited by 53
“In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/ hyperactivity disorder and schizophrenia (Swanson et al. 2006; Minzemberg & Carter 2008).”
BackgroundPieramico, V., Esposito, R., Cesinaro, S., Frazzini, V., & Sensi, S. L. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00153 · Cited by 61
“…models (Béracochéa et al., 2002) or humans (Turner et al., 2003; Baranski et al., 2004; Muller et al., 2004; Randall et al., 2005), are focused on effects on attention and working memory while other cognitive domains (such as long-term memory) are often neglected (Minzenberg and Carter, 2008).”
BackgroundThe relationship between sleep quality and neurocognition in bipolar disorder
Russo, M., Mahon, K., Shanahan, M., Ramjas, E., Solon, C., Purcell, S. M., & Burdick, K. E. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.08.009 · Cited by 47
“Among the most persistent symptoms are circadian-based sleep and daytime activity abnormalities, often associated with anergia and psychomotor retardation (Mitchell and Malhi, 2004).”
BackgroundHeal, D. J., Buckley, N., Gosden, J., Slater, N., France, C. P., & Hackett, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.021 · Cited by 55
“Modafinil is an unusual stimulant with enigmatic pharmacology (see reviews by Minzenberg and Carter, 2008; Heal et al., 2012a).”
Modafinil May Alleviate Poststroke Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial
Poulsen, M. B., Damgaard, B., Zerahn, B., Overgaard, K., & Rasmussen, R. S. (2015) · Stroke · doi:10.1161/strokeaha.115.010860 · Cited by 54
“whether these effects are direct or a consequence of changes in the catecholamine system.(16) The pharmacological profile is distinct from amphetamine,(17) and modafinil has fewer adverse effects, little potential for abuse and no withdrawal reactions.”
BackgroundModulation of Fronto-Cortical Activity by Modafinil: A Functional Imaging and Fos Study in the Rat
Gozzi, A., Colavito, V., Etet, P. F. S., Montanari, D., Fiorini, S., Tambalo, S., Bifone, A., Zucconi, G. G., & Bentivoglio, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.260 · Cited by 52
“These findings are consistent with the different pharmacological profile of the two drugs (Minzenberg and Carter, 2007), and suggest that MOD can focally activate brain substrates of arousal and cognition, which, in the case of amphetamine, appear to be recruited as a result of a global psychostimulant effect.”
BackgroundResultInfluentialEffects of Modafinil on the Sleep EEG Depend on Val158Met Genotype of COMT
Bodenmann, S., & Landolt, H.-P. (2010) · Sleep · doi:10.1093/sleep/33.8.1027 · Cited by 49
Arnold, V. K., Feifel, D., Earl, C. Q., Yang, R., & Adler, L. A. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712441969 · Cited by 48
“Although it is thought to be structurally and pharmacologically different from amphetamine, with a distinct mechanism of action (Minzenberg & Carter, 2008; Turner et al., 2004), preclinical studies of modafinil in animals and a pilot study in male volunteers have demonstrated dopaminergic activity,…”
BackgroundMethodInfluentialWilliams, S. C., Marshall, N. S., Kennerson, M. L., Rogers, N. L., Liu, P. Y., & Grunstein, R. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200908-1307oc · Cited by 50
“Modafinil induces wakefulness primarily by inhibiting dopamine and noradrenaline reuptake transporters (8).”
Mahler, S. V., Hensley-Simon, M., Tahsili-Fahadan, P., LaLumiere, R. T., Thomas, C., Fallon, R. V., Kalivas, P. W., & Aston-Jones, G. (2014) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00506.x · Cited by 48
“Indeed, a primary effect of modafinil is to inhibit dopamine transport, which typically promotes rather than inhibits motivated behavior.”
Rudolf, J., Dondorp, D., Canon, L., Tieo, S., & Chatzigeorgiou, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-38791-5 · Cited by 54
Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis
Fiscon, G., Conte, F., Amadio, S., Volonté, C., & Paci, P. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01064-z · Cited by 49
Dejban, P., Eslami, F., Rahimi, N., Takzare, N., Jahansouz, M., & Dehpour, A. R. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173579 · Cited by 47
“TNF-α and IL-1β levels are presented as pg/ml.”
BackgroundInfluentialModafinil Treatment for Fatigue in HIV/AIDS: A Randomized Placebo-Controlled Study
Rabkin, J. G., McElhiney, M. C., Rabkin, R., & McGrath, P. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05171bro · Cited by 47
Tahsili‐Fahadan, P., Carr, G. V., Harris, G. C., & Aston‐Jones, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.94 · Cited by 48
“Modafinil (2-diphenylmethyl-sulfinyl-2 acetamide) is a wake-promoting agent approved for the treatment of narcolepsy, obstructive sleep apnea, and shift-work sleep disorders (Minzenberg and Carter, 2008).”
The psychostimulant modafinil enhances gap junctional communication in cortical astrocytes
Liu, X., Petit, J.-M., Ezan, P., Gyger, J., Magistretti, P. J., & Giaume, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.019 · Cited by 47
“Asmodafinil has been shown to influence multiple neurotransmission systems in the central nervous system and its mode of action still remains elusive (Minzenberg and Carter, 2008), the exact mechanism by which modafinil influences astroglial networks was beyond the scope of this work.”
Dawson, N., Thompson, R. J., McVie, A., Thomson, D. M., Morris, B. J., & Pratt, J. A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq090 · Cited by 47
Becker, M., Repantis, D., Dresler, M., & Kühn, S. (2022) · Human Brain Mapping · doi:10.1002/hbm.25949 · Cited by 53
Fox, H., & Sinha, R. (2014) · Advances in Pharmacology · doi:10.1016/b978-0-12-420118-7.00006-8 · Cited by 46
“This is thought to be due to fact that modafinil has a markedly lower affinity for DAT binding compared with other stimulants (Minzenberg & Carter, 2008).”
BackgroundJin-xia, H., Chen, D., Liu, D., & Zhu, Y. (2017) · Inflammopharmacology · doi:10.1007/s10787-017-0387-3 · Cited by 49
Kim, W., Tateno, A., Arakawa, R., Sakayori, T., Ikeda, Y., Suzuki, H., & Okubo, Y. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001612 · Cited by 44
“Modafinil may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders (i.e. schizophrenia, attention-deficit/hyperactivity disorder [ADHD]) (Minzenberg and Carter, 2008).”
BackgroundManaging fatigue in sarcoidosis – A systematic review of the evidence
Atkins, C., & Wilson, A. M. (2016) · Chronic Respiratory Disease · doi:10.1177/1479972316661926 · Cited by 46
“They have a complex profile of neurochemical effects which are different to those of amphetamines.(21) Finally, physical activity programmes, including pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD) patients, have been shown to have wide reaching benefits, including improving dyspnoea scores,…”
BackgroundDaubner, J., Arshaad, M. I., Henseler, C., Hescheler, J., Ehninger, D., Broich, K., Rawashdeh, O., Papazoglou, A., & Weiergräber, M. (2021) · Neural Plasticity · doi:10.1155/2021/8823383 · Cited by 52
“In addition, modafinil was reported to serve as an inhibitor of the norepinephrine transporter (NET) [157].”
BackgroundKochman, L. J., Fornal, C. A., & Jacobs, B. L. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06759.x · Cited by 45
“Its mode of action is currently unknown, but may involve modulation of multiple neurotransmitter systems (reviewed by Minzenberg & Carter, 2008).”
BackgroundMonoamine Reuptake Inhibitors in Parkinson’s Disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2015) · Parkinson s Disease · doi:10.1155/2015/609428 · Cited by 48
“Modafinil 3,190 (EC50)–6,390 (EC50) 35,600 (EC50) >500,000 (EC50) [341, 357, 358]”
BackgroundBrown, J. W., Rueter, L. E., & Zhang, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.11.008 · Cited by 45
Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil
Niepel, G., Bibani, R. H., Vilisaar, J., Langley, R. W., Bradshaw, C. M., Szabadi, E., & Constantinescu, C. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.036 · Cited by 49
Gan, S. I., de Jongh, M., & Kaplan, M. M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0613-3 · Cited by 47
“Modafinil does not have any known addictive properties [19, 20] but remains a class IV controlled substance.”
BackgroundBystritsky, A., Kerwin, L. E., & Feusner, J. D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08l04641 · Cited by 40
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42
Gilleen, J., Michalopoulou, P. G., Reichenberg, A., Drake, R., Wykes, T., Lewis, S. W., & Kapur, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.01.001 · Cited by 49
“Therapeutically, if modafinil could improve cognitive functioning it may offer advantages over compounds such as amphetamine and Ldopa particularly if administration is required repeatedly over time as it is associated with low risk of abuse and has limited side-effects, which are well-tolerated and reversible (Minzen…”
InfluentialMohamed, A. D. (2016) · The Journal of Creative Behavior · doi:10.1002/jocb.73 · Cited by 41
The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis
Kredlow, M. A., Keshishian, A. C., Oppenheimer, S., & Otto, M. W. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001085 · Cited by 46
Metadata
- Authors
- Minzenberg, M. J., & Carter, C. S.
- Affiliations
- University of California Davis Medical Center (US)
- Corresponding author
- Minzenberg, Michael J
- Venue
- Neuropsychopharmacology
- Published
- 2007-08-22
- Volume
- 33
- Issue
- 7
- Pages
- 1477-1502
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2122011624
- Semantic Scholar
- cf5b2a15296e7832bcfdd965f28583772ef2999c
- Cited by
- 713
- References
- 215
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 25 · 2023: 33 · 2022: 33 · 2021: 46 · 2020: 26 · 2019: 19 · 2018: 33 · 2017: 42 · 2016: 22 · 2015: 49 · 2014: 48 · 2013: 62 · 2012: 59
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 59883, MH066629, R01MH059883, R01MH066629)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- modafinil, wakefulness-promoting agents, neurochemical mechanisms, cognition, catecholamines, serotonin, glutamate, GABA, orexin, histamine, working memory, episodic memory, prefrontal cortex, cognitive control, treatment-resistant depression, attention deficit hyperactivity disorder, schizophrenia, cognitive impairment, pharmacokinetics, abuse liability
- MeSH terms
- Modafinil, Animals, Mental Disorders, Benzhydryl Compounds, Brain Chemistry, Cognition, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.